
Metcard 25 Tablet ER
Marketer
Pharma Planet India
Salt Composition
Metoprolol Succinate (23.75mg)
Overview Metcard 25 Tablet ER
Extended-release Metoprolol Succinate 25 mg tablets are classified as beta-adrenergic blocking agents. This medication treats hypertension (high blood pressure), angina pectoris (chest pain from heart conditions), and cardiac arrhythmias (irregular heartbeats). It also helps prevent migraines, recurrent heart attacks, and strokes. Metoprolol Succinate may be administered alone or in combination with other drugs. Dosage and frequency depend on the treated condition and its severity. It can be taken with or without food, but consistent daily timing is crucial for optimal efficacy. Full therapeutic benefit may take weeks to manifest, and lifelong use may be necessary. Continued use is vital even during symptom remission; discontinuation can exacerbate underlying conditions. Common, typically mild and transient, adverse effects include fatigue, cephalalgia (headache), depressive symptoms, diarrhea, skin rash, bradycardia (slow heart rate), dizziness, and nausea. Less frequently, shortness of breath or hypotension (low blood pressure) may occur. To minimize adverse reactions, your physician will likely initiate treatment with a low dose, gradually increasing it as needed. Report any persistent or bothersome side effects to your doctor. Prior to commencing therapy, disclose any liver disorders. This medication is contraindicated in patients with bradycardia, severe peripheral vascular disease, severe congestive heart failure, or hypotension. Pregnant or lactating individuals should seek medical counsel before use. Always consult your physician to determine suitability and monitor blood pressure regularly to assess treatment effectiveness. Alcohol consumption should be avoided due to potential exacerbation of side effects.
Uses of Metcard 25 Tablet ER
Management of angina pectoris|Cardiac arrhythmia management|Mitigation of myocardial infarction|Hypertension therapy|Migraine prophylaxis
Major Benefits of Metcard 25 Tablet ER:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the tablet whole; do not crush, chew, or divide it. Metcard 25 Tablet ER can be administered with or without food, but consistent timing is recommended. Limit consumption of Metcard 25 Tablet ER with high-fat foods including olive oil, nuts and seeds (like Brazil nuts), dark chocolate, butter, and red meat.
Common Side effects of Metcard 25 Tablet ER:
- Tiredness
- Dizziness
- Depression
- Breathlessness
- Headache
- Slow heart rate
- Nausea
- Rash
- Diarrhea
- Hypotension (low blood pressure)
How to use Metcard 25 Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Metcard 25 Tablet ER whole; avoid chewing, crushing, or breaking it. This medication can be taken with or without food, but consistent timing is recommended. Minimize consumption of Metcard 25 Tablet ER with high-fat foods like olive oil, nuts (including Brazil nuts), dark chocolate, butter, and red meat.
How Metcard 25 Tablet ER works:
Extended-release Metcard 25mg tablets are a cardioselective beta-adrenergic blocking agent. This medication reduces heart rate and improves the heart's pumping efficiency, thus enhancing circulatory function.
SAFETY ADVICE
AlcoholUNSAFE
Combining Metcard 25 Tablet ER and alcohol is inadvisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
Extended-release Metcard 25mg tablets may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Extended-release Metcard 25mg tablets are likely safe for breastfeeding mothers. Available evidence from human studies indicates minimal risk to the infant.
DrivingUNSAFE
Extended-release Metcard 25mg tablets can cause drowsiness, blurred vision, and dizziness. Driving is inadvisable if these effects are experienced.
KidneySAFE IF PRESCRIBED
Metcard 25 Extended-Release tablets pose no safety concerns for patients with renal impairment; dose modification is unnecessary.
LiverCAUTION
Individuals with hepatic impairment should exercise caution when using Metcard 25 Extended-Release tablets. Dosage modification of Metcard 25 ER may be necessary. Physician consultation is advised.
What if you forget to take Metcard 25 Tablet ER :
Should you forget a Metcard 25 Tablet ER dose, take it immediately. However, if your next dose is imminent, omit the missed dose and resume your usual dosing schedule. Avoid taking a double dose.
Facts to Know About Metcard 25 Tablet ER
| Label | Value |
|---|---|
| Chemical Type | Alcohols and Phenols |
| Developing Habits | No. |
| Treatment Category | Heart |
